stockrowIovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
Follow IOVA
Alert me
Iovance Biotherapeutics, Inc. (IOVA) Shares outstanding
Iovance Biotherapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $357.3M, up 23.3% from $289.9M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $450.2M. Over the past ten years it has ranged from $44.4M (fiscal 2015) to $357.3M (fiscal 2025) — the current reading is the highest in ten years. Iovance Biotherapeutics, Inc. ranks 10th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $357.3M | 23.27% |
| FY2024 | $289.9M | 23.28% |
| FY2023 | $235.1M | 47.64% |
| FY2022 | $159.3M | 3.82% |
| FY2021 | $153.4M | 10.92% |
| FY2020 | $138.3M | 11.23% |
| FY2019 | $124.3M | 27.82% |
| FY2018 | $97.3M | 49.10% |
| FY2017 | $65.2M | 18.05% |
| FY2016 | $55.3M | 24.45% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $450.2M | 7.57% |
| Mar 2026 | $418.5M | 17.12% |
| Dec 2025 | $357.3M | (1.84%) |
| Sep 2025 | $364.0M | 8.83% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IOVA Iovance Biotherapeutics, Inc. | $450.2M |
| ABCL AbCellera Biologics Inc. compare | $305.6M |
| RLAY Relay Therapeutics, Inc. compare | $202.8M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $175.5M |
| TNGX Tango Therapeutics, Inc. compare | $149.9M |
| EWTX Edgewise Therapeutics, Inc. compare | $107.7M |
| XENE Xenon Pharmaceuticals Inc. compare | $99.6M |
| IRON Disc Medicine, Inc. compare | $38.7M |
| PBLS Parabilis Medicines, Inc. compare | $28.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on IOVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Altman Z-score
- The full statement